亚太慢病毒载体市场 – 行业趋势及 2028 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

亚太慢病毒载体市场 – 行业趋势及 2028 年预测

  • Healthcare
  • Published Report
  • Jun 2021
  • Asia-Pacific
  • 350 页面
  • 桌子數: 212
  • 图号: 52

>亚太慢病毒载体市场,按组件(慢病毒启动子、慢病毒融合标签、慢病毒包装系统、其他)、类型(产品、服务)、代数(第 4 代、第 3 代、第 2 代、第 1 代)、工作流程(上游处理、下游处理)、递送方式(体内、体外)、疾病指征(癌症、遗传性疾病、传染病、兽医疾病、其他)、应用(基因治疗、疫苗学)、最终用户(生物技术公司、制药公司、合同研究组织、合同开发和制造组织 (CDMO)、学术/研究机构)、国家(日本、中国、韩国、印度、澳大利亚、新加坡、泰国、马来西亚、印度尼西亚、菲律宾、亚太其他地区)划分的行业趋势和预测到 2028 年

亚太慢病毒载体市场

市场分析与洞察:亚太慢病毒载体市场

慢病毒载体市场预计将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析,在 2021 年至 2028 年的预测期内,该市场以 16.1% 的复合年增长率增长,预计到 2028 年将达到 2.0737 亿美元。慢病毒载体的需求不断增长和传染病的增加是预测期内推动市场需求的主要驱动力。

慢病毒载体 (LV) 是哺乳动物细胞中基因转移的有效载体,因为它们能够在非分裂细胞和分裂细胞中稳定表达目标基因。慢病毒是人类和动物病原体,已知其潜伏期长且感染持续。从初次感染到出现首批症状之间的时间可能长达数月或数年。

分子生物学家经常使用病毒载体将遗传物质运送到细胞中。这个过程可以在体内(活体生物体内)或细胞培养(体外)中进行。病毒已经发展出专门的分子机制,可以有效地将其基因组运送到它们感染的细胞内。

在此次 Covid-19 爆发期间,老年人口的增长和对疫苗开发的需求有效地促进了慢病毒载体市场的增长。然而,慢病毒载体缺乏可扩展性和下游纯化的局限性可能会阻碍慢病毒载体市场的未来增长。主要市场参与者的战略举措和基因组学资金的增加为亚太地区慢病毒载体市场的增长提供了机遇。与慢病毒载体产品相关的严格监管政策和副作用对未来的市场增长构成了挑战。

The lentiviral vector market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

亚太慢病毒载体市场

Asia-Pacific Lentiviral Vector Market Scope and Market Size

The lentiviral vector market is segmented into eight notable segments which are based on the component, type, generation, workflow, delivery method, disease indication, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of component, the lentiviral vector market is segmented into lentiviral promoter, lentiviral fusion tags, lentivirus packaging systems and other. In 2021, lentivirus packaging systems segment is expected to dominate the lentiviral vector market due to rising research advancements in China, and Japan and other countries in the Asia-Pacific.
  • On the basis of type, the lentiviral vector market is segmented into product and services. In 2021, product segment is expected to dominate the lentiviral vector market due to high geriatric population.
  • On the basis of generation, the lentiviral vector market is segmented into 4th-generation, 3rd-generation, 2nd-generation and 1st-generation. In 2021, 4th-generation segment is expected to dominate the lentiviral vector market due to its less side effects associated with gene therapy applications.
  • On the basis of workflow, the lentiviral vector market is segmented into upstream processing and downstream processing. In 2021, upstream processing segment is expected to dominate the lentiviral vector market due to rising skilled workforces in research institutes and pharma companies.
  • On the basis of delivery method, the lentiviral vector market is segmented into in vivo and ex vivo. In 2021, in vivo segment is expected to dominate the lentiviral vector market due to rising development in clinical trials for viral vectors.
  • On the basis of disease indication, the lentiviral vector market is segmented into cancer, genetic disorders, infectious diseases, veterinary disease and other. In 2021, cancer segment is expected to dominate the lentiviral vector market due to high population and prevalence of cancer cases.
  • On the basis of application, the lentiviral vector market is segmented into gene therapy and vaccinology. In 2021, gene therapy segment is expected to dominate the lentiviral vector market due to wide spread medical tourism in Asian countries.
  • On the basis of end user, the lentiviral vector market is segmented into biotechnology companies, pharmaceutical companies, contract research organizations, contract development and manufacturing organization (CDMO) and academic/ research institutes. In 2021, academic/ research institutes segment is expected to dominate the lentiviral vector market due to rising government fund for research and development procedures.

Lentiviral Vector Market Country Level Analysis

The lentiviral vector market is analysed and market size information is provided by the country, component, type, generation, workflow, delivery method, disease indication, application and end user as referenced above.

The countries covered in the lentiviral vector market report in this region are China, Japan, Australia, India, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific.

Products segment is dominating in China which is leading in the Asia-Pacific region due to high geriatric population and high vaccine production.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Strategic Initiatives by Manufactures is Creating New Opportunities for Players in the Lentiviral Vector Market 

Lentiviral vector market also provides you with detailed market analysis for every country growth. Moreover, it provides detail data regarding growth in lentiviral vector sales, partnership, acquisition, distribution agreement among the market players of Asia-Pacific region. The data is available for historic period 2010 to 2019.  

Competitive Landscape and Lentiviral Vector Market Share Analysis

Lentiviral vector market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to lentiviral vector market.

从事慢病毒载体业务的主要公司包括 Merck KGaA、FinVector Oy、Oxford Biomedica、Sirion-Biotech GmbH、Thermo Fisher Scientific Inc.、Applied Biological Materials Inc.、Creative Biolabs、Batavia Biosciences BV、Waisman Biomanufacturing、Cytiva(Danaher 的子公司)、bluebird bio, Inc.、System Biosciences, LLC、COBRA BIOLOGICS、Takara Bio Inc.、OriGene Technologies, Inc.、Sino Biological, Inc.、Cell Biolabs, Inc.、Lonza、GENEMEDI 和 FUJIFILM Diosynth Biotechnologies(FUJIFILM Holdings Corporation 的子公司)以及其他国内参与者。DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。

全球各地的公司也签订了许多合同和协议,这也加速了慢病毒载体市场的发展。

例如,

  • 2021 年 2 月,赛默飞世尔科技公司宣布在年度 CMO 领导力奖中获得六个奖项。生命科学领袖和外包制药公司颁发的奖项旨在表彰生物制药和生物技术公司评选出的顶级合同制造合作伙伴。据估计,这一认可有望加强其全球影响力,并在未来几年推动其增长。

市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业等策略正在增强公司在慢病毒载体市场的影响力,这也为组织的利润增长带来了好处。

 

 


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA-PACIFIC LENTIVIRAL VECTOR MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 COMPONENT LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET APPLICATION COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 ADHERENT AND SUSPENSION CULTURES: OVERVIEW

4.2 PRICING OF LENTIVIRAL VECTORS: PRODUCT AND SERVICE

4.2.1 PRODUCT

4.2.2 SERVICES

5 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: REGULATORY FRAMEWORK

5.1 REGULATION IN THE UNITED STATES

5.2 REGULATIONS IN EUROPE

5.3 REGULATIONS IN INDIA

5.4 REGULATIONS IN JAPAN

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISE IN DEMAND FOR VIRAL VECTORS

6.1.2 EMERGENCE OF COVID-19 AND DEMAND FOR VACCINE DEVELOPMENT

6.1.3 BENEFITS OF VIRAL VECTORS FOR GENE THERAPY

6.1.4 RISE IN NUMBER OF INFECTIOUS DISEASES

6.1.5 GROWING GERIATRIC POPULATION

6.2 RESTRAINTS

6.2.1 LACK OF SCALABILITY

6.2.2 LIMITATIONS OF DOWNSTREAM PURIFICATION

6.2.3 SHORTAGE OF SKILLED PERSONNELS

6.3 OPPORTUNITIES

6.3.1 INCREASED HEALTHCARE FACILITY AND FUNDING FOR GENOMICS

6.3.2 RISE IN TECHNOLOGICAL ADVANCEMENT

6.3.3 INCREASE IN DEMAND FOR PERSONALIZED MEDICINES

6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS

6.4 CHALLENGES

6.4.1 STRINGENT GOVERNMENT APPROVAL POLICIES

6.4.2 SIDE-EFFECTS ASSOCIATED WITH LENTIVIRAL VECTORS INTEGRATION

7 IMPACT OF COVID-19 ON THE ASIA-PACIFIC LENTIVIRAL VECTOR MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT ON DEMAND

7.3 IMPACT ON SUPPLY CHAIN

7.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS

7.5 CONCLUSION

8 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT

8.1 OVERVIEW

8.2 LENTIVIRUS PACKAGING SYSTEMS

8.3 LENTIVIRAL PROMOTER

8.3.1 LENTIVIRUS PROMOTER VECTORS

8.3.2 LENTIVIRUS PROMOTERLESS VECTORS

8.4 LENTIVIRAL FUSION TAGS

8.5 OTHERS

9 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY TYPE

9.1 OVERVIEW

9.2 PRODUCT

9.2.1 HUMAN IMMUNODEFICIENCY VIRUS (HIV)

9.2.2 FELINE IMMUNODEFICIENCY VIRUS (FIV)

9.2.3 EQUINE INFECTIOUS ANEMIA VIRUS (EIAV)

9.3 SERVICES

10 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY GENERATION

10.1 OVERVIEW

10.2 4TH GENERATION

10.3 3RD GENERATION

10.4 2ND GENERATION

10.5 1ST GENERATION

11 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY WORKFLOW

11.1 OVERVIEW

11.2 UPSTREAM PROCESSING

11.2.1 VECTOR AMPLIFICATION & EXPANSION

11.2.2 VECTOR RECOVERY/ HARVESTING

11.3 DOWNSTREAM PROCESSING

11.3.1 PURIFICATION

11.3.2 FILL-FINISH

12 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD

12.1 OVERVIEW

12.2 IN-VIVO

12.3 EX-VIVO

13 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION

13.1 OVERVIEW

13.2 CANCER

13.3 GENETIC DISORDERS

13.3.1 B-THALESSEMIA

13.3.2 X-LINKED ADRENO LEUKODYSTROPHY

13.3.3 METACHROMATIC LEUKODYSTROPHY

13.3.4 WISKOTT-ALDRICH SYNDROME

13.3.5 OTHERS

13.4 INFECTIOUS DISEASES

13.4.1 HIV

13.4.2 OTHERS

13.5 VETERINARY DISEASES

13.6 OTHERS

14 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY APPLICATION

14.1 OVERVIEW

14.2 GENE THERAPY

14.2.1 RECOMBINANT PROTEIN EXPRESSION

14.2.2 FUNCTIONAL ASSAYS

14.2.3 IN VITRO TRANSCRIPTION

14.2.4 PROTEIN CHARACTERIZATION

14.2.5 OTHERS

14.3 VACCINOLOGY

15 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY END USER

15.1 OVERVIEW

15.2 ACADEMIC/ RESEARCH INSTITUTES

15.3 PHARMACEUTICAL COMPANIES

15.4 CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS

15.5 BIOTECHNOLOGY COMPANIES

15.6 CONTRACT RESEARCH ORGANIZATIONS

16 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY REGION

16.1 ASIA-PACIFIC

16.1.1 CHINA

16.1.2 JAPAN

16.1.3 AUSTRALIA

16.1.4 INDIA

16.1.5 SOUTH KOREA

16.1.6 SINGAPORE

16.1.7 MALAYSIA

16.1.8 THAILAND

16.1.9 INDONESIA

16.1.10 PHILIPPINES

16.1.11 REST OF ASIA-PACIFIC

17 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

18 SWOT

19 COMPANY PROFILE

19.1 OXFORD BIOMEDICA

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 THERMO FISHER SCIENTIFIC INC.

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 MERCK KGAA

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENT

19.4 LONZA

19.4.1 COMPANY SNAPSHOT

19.4.2 RECENT ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 CYTIVA (A SUBSIDIARY OF DANAHER)

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 PRODUCT PORTFOLIO

19.5.4 RECENT DEVELOPMENT

19.6 APPLIED BIOLOGICAL MATERIALS INC.

19.6.1 COMPANY SNAPSHOT

19.6.2 PRODUCT PORTFOLIO

19.6.3 RECENT DEVELOPMENT

19.7 BATAVIA BIOSCIENCES B.V.

19.7.1 COMPANY SNAPSHOT

19.7.2 PRODUCT PORTFOLIO

19.7.3 RECENT DEVELOPMENT

19.8 BLUEBIRD BIO, INC.

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENTS

19.9 CELL BIOLABS, INC.

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENT

19.1 CREATIVE BIOLABS

19.10.1 COMPANY SNAPSHOT

19.10.2 SERVICE PORTFOLIO

19.10.3 RECENT DEVELOPMENT

19.11 COBRA BIOLOGICS LIMITED

19.11.1 COMPANY SNAPSHOT

19.11.2 PRODUCT PORTFOLIO

19.11.3 RECENT DEVELOPMENTS

19.12 FINVECTOR OY

19.12.1 COMPANY SNAPSHOT

19.12.2 SERVICE PORTFOLIO

19.12.3 RECENT DEVELOPMENT

19.13 FUJIFIM DIOSYNTH BIOTECHNOLOGIES (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)

19.13.1 COMPANY SNAPSHOT

19.13.2 RECENT ANALYSIS

19.13.3 SERVICE PORTFOLIO

19.13.4 RECENT DEVELOPMENTS

19.14 GENEMEDI

19.14.1 COMPANY SNAPSHOT

19.14.2 PRODUCT PORTFOLIO

19.14.3 RECENT DEVELOPMENT

19.15 ORIGENE TECHNOLOGIES, INC.

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENTS

19.16 SINO BIOLOGICAL, INC.

19.16.1 COMPANY SNAPSHOT

19.16.2 PRODUCT PORTFOLIO

19.16.3 RECENT DEVELOPMENT

19.17 SIRION-BIOTECH GMBH

19.17.1 COMPANY SNAPSHOT

19.17.2 PRODUCT PORTFOLIO

19.17.3 RECENT DEVELOPMENTS

19.18 SYSTEM BIOSCIENCES, LLC

19.18.1 COMPANY SNAPSHOT

19.18.2 PRODUCT PORTFOLIO

19.18.3 RECENT DEVELOPMENTS

19.19 TAKARA BIO INC.

19.19.1 COMPANY SNAPSHOT

19.19.2 RECENT ANALYSIS

19.19.3 PRODUCT PORTFOLIO

19.19.4 RECENT DEVELOPMENTS

19.2 WAISMAN BIOMANUFACTURING

19.20.1 COMPANY SNAPSHOT

19.20.2 PRODUCT PORTFOLIO

19.20.3 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

表格列表

TABLE 1 THERMO FISHER SCIENTIFIC

TABLE 2 THE REGENTS OF THE UNIVERSITY OF MICHIGAN

TABLE 3 KERAFAST

TABLE 4 APPLIED BIOLOGICAL MATERIALS INC.

TABLE 5 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 6 ASIA-PACIFIC LENTIVIRUS PACKAGING SYSTEMS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 ASIA-PACIFIC LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 ASIA-PACIFIC LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 9 ASIA-PACIFIC LENTIVIRAL FUSION TAGS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 ASIA-PACIFIC OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 12 ASIA-PACIFIC PRODUCT IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 ASIA-PACIFIC PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 14 ASIA-PACIFIC SERVICES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 16 ASIA-PACIFIC 4TH-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 ASIA-PACIFIC 3RD-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 ASIA-PACIFIC 2ND-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 ASIA-PACIFIC 1ST-GENERATION IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY WORK FLOW, 2019-2028 (USD MILLION)

TABLE 21 ASIA-PACIFIC UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 ASIA-PACIFIC UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 23 ASIA-PACIFIC DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 ASIA-PACIFIC DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 25 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 26 ASIA-PACIFIC IN-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 ASIA-PACIFIC EX-VIVO IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 29 ASIA-PACIFIC CANCER IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 ASIA-PACIFIC GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 ASIA-PACIFIC GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 32 ASIA-PACIFIC INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 ASIA-PACIFIC INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 34 ASIA-PACIFIC VETERINARY DISEASES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 ASIA-PACIFIC OTHERS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 37 ASIA-PACIFIC GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 ASIA-PACIFIC GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 39 ASIA-PACIFIC VACCINOLOGY IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 41 ASIA-PACIFIC ACADEMIC/ RESEARCH INSTITUTES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 ASIA-PACIFIC PHARMACEUTICAL COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 ASIA-PACIFIC CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 ASIA-PACIFIC BIOTECHNOLOGY COMPANIES IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 ASIA-PACIFIC CONTRACT RESEARCH ORGANIZATIONS IN LENTIVIRAL VECTOR MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 47 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 48 ASIA-PACIFIC LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 49 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 50 ASIA-PACIFIC PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 51 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 52 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 53 ASIA-PACIFIC UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 54 ASIA-PACIFIC DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 55 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 56 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 57 ASIA-PACIFIC GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 58 ASIA-PACIFIC INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 59 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 60 ASIA-PACIFIC GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 61 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 62 CHINA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 63 CHINA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 64 CHINA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 65 CHINA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 66 CHINA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 67 CHINA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 68 CHINA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 69 CHINA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 70 CHINA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 71 CHINA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 72 CHINA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 73 CHINA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 74 CHINA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 75 CHINA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 76 CHINA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 77 JAPAN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 78 JAPAN LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 79 JAPAN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 80 JAPAN PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 81 JAPAN LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 82 JAPAN LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 83 JAPAN UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 84 JAPAN DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 85 JAPAN LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 86 JAPAN LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 87 JAPAN GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 88 JAPAN INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 89 JAPAN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 90 JAPAN GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 91 JAPAN LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 92 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 93 AUSTRALIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 94 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 95 AUSTRALIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 96 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 97 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 98 AUSTRALIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 99 AUSTRALIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 100 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 101 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 102 AUSTRALIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 103 AUSTRALIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 104 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 105 AUSTRALIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 106 AUSTRALIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 107 INDIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 108 INDIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 109 INDIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 110 INDIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 111 INDIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 112 INDIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 113 INDIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 114 INDIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 115 INDIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 116 INDIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 117 INDIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 118 INDIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 119 INDIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 120 INDIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 121 INDIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 122 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 123 SOUTH KOREA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 124 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 125 SOUTH KOREA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 126 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 127 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 128 SOUTH KOREA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 129 SOUTH KOREA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 130 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 131 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 132 SOUTH KOREA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 133 SOUTH KOREA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 134 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 135 SOUTH KOREA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 136 SOUTH KOREA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 137 SINGAPORE LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 138 SINGAPORE LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 139 SINGAPORE LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 140 SINGAPORE PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 141 SINGAPORE LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 142 SINGAPORE LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 143 SINGAPORE UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 144 SINGAPORE DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 145 SINGAPORE LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 146 SINGAPORE LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 147 SINGAPORE GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 148 SINGAPORE INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 149 SINGAPORE LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 150 SINGAPORE GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 151 SINGAPORE LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 152 MALAYSIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 153 MALAYSIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 154 MALAYSIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 155 MALAYSIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 156 MALAYSIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 157 MALAYSIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 158 MALAYSIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 159 MALAYSIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 160 MALAYSIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 161 MALAYSIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 162 MALAYSIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 163 MALAYSIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 164 MALAYSIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 165 MALAYSIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 166 MALAYSIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 167 THAILAND LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 168 THAILAND LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 169 THAILAND LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 170 THAILAND PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 171 THAILAND LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 172 THAILAND LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 173 THAILAND UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 174 THAILAND DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 175 THAILAND LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 176 THAILAND LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 177 THAILAND GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 178 THAILAND INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 179 THAILAND LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 180 THAILAND GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 181 THAILAND LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 182 INDONESIA LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 183 INDONESIA LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 184 INDONESIA LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 185 INDONESIA PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 186 INDONESIA LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 187 INDONESIA LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 188 INDONESIA UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 189 INDONESIA DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 190 INDONESIA LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 191 INDONESIA LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 192 INDONESIA GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 193 INDONESIA INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 194 INDONESIA LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 195 INDONESIA GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 196 INDONESIA LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 197 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 198 PHILIPPINES LENTIVIRAL PROMOTER IN LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

TABLE 199 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 200 PHILIPPINES PRODUCT IN LENTIVIRAL VECTOR MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 201 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY GENERATION, 2019-2028 (USD MILLION)

TABLE 202 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY WORKFLOW, 2019-2028 (USD MILLION)

TABLE 203 PHILIPPINES UPSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 204 PHILIPPINES DOWNSTREAM PROCESSING IN LENTIVIRAL VECTOR MARKET, BY METHOD, 2019-2028 (USD MILLION)

TABLE 205 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY DELIVERY METHOD, 2019-2028 (USD MILLION)

TABLE 206 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY DISEASE INDICATION, 2019-2028 (USD MILLION)

TABLE 207 PHILIPPINES GENETIC DISORDERS IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 208 PHILIPPINES INFECTIOUS DISEASES IN LENTIVIRAL VECTOR MARKET, BY DISEASE, 2019-2028 (USD MILLION)

TABLE 209 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 210 PHILIPPINES GENE THERAPY IN LENTIVIRAL VECTOR MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 211 PHILIPPINES LENTIVIRAL VECTOR MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 212 REST OF ASIA-PACIFIC LENTIVIRAL VECTOR MARKET, BY COMPONENT, 2019-2028 (USD MILLION)

图片列表

FIGURE 1 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 11 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: SEGMENTATION

FIGURE 12 GROWING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE ASIA-PACIFIC LENTIVIRAL VECTOR MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 LENTIVIRUS PACKAGING SYSTEMS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LENTIVIRAL VECTOR MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA-PACIFIC LENTIVIRAL VECTOR MARKET

FIGURE 15 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, 2020

FIGURE 16 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, 2019-2028 (USD MILLION)

FIGURE 17 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, CAGR (2021-2028)

FIGURE 18 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT, LIFELINE CURVE

FIGURE 19 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, 2020

FIGURE 20 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, 2019-2028 (USD MILLION)

FIGURE 21 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 22 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY TYPE, LIFELINE CURVE

FIGURE 23 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, 2020

FIGURE 24 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, 2019-2028 (USD MILLION)

FIGURE 25 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, CAGR (2021-2028)

FIGURE 26 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY GENERATION, LIFELINE CURVE

FIGURE 27 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, 2020

FIGURE 28 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, 2019-2028 (USD MILLION)

FIGURE 29 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, CAGR (2021-2028)

FIGURE 30 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY WORK FLOW, LIFELINE CURVE

FIGURE 31 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, 2020

FIGURE 32 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, 2019-2028 (USD MILLION)

FIGURE 33 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, CAGR (2021-2028)

FIGURE 34 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DELIVERY METHOD, LIFELINE CURVE

FIGURE 35 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, 2020

FIGURE 36 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, 2019-2028 (USD MILLION)

FIGURE 37 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, CAGR (2021-2028)

FIGURE 38 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY DISEASE INDICATION, LIFELINE CURVE

FIGURE 39 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, 2020

FIGURE 40 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, 2019-2028 (USD MILLION)

FIGURE 41 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 42 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 43 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, 2020

FIGURE 44 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, 2019-2028 (USD MILLION)

FIGURE 45 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, CAGR (2021-2028)

FIGURE 46 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: SNAPSHOT (2020)

FIGURE 48 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COUNTRY (2020)

FIGURE 49 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COUNTRY (2021 & 2028)

FIGURE 50 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COUNTRY (2020 & 2028)

FIGURE 51 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: BY COMPONENT (2021-2028)

FIGURE 52 ASIA-PACIFIC LENTIVIRAL VECTOR MARKET: COMPANY SHARE 2020 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Asia-Pacific Lentiviral Vector Market is projected to grow at a CAGR of 16.1% during the forecast period by 2028.
The future market value of the Asia-Pacific Lentiviral Vector Market is expected to reach USD 207.37 million by 2028.
The major players in the Asia-Pacific Lentiviral Vector Market are Merck KGaA, FinVector Oy, Oxford Biomedica, Sirion-Biotech GmbH, Thermo Fisher Scientific Inc., Applied Biological Materials Inc., Creative Biolabs, Batavia Biosciences B.V., etc.
The countries covered in the Asia-Pacific Lentiviral Vector Market are China, Japan, Australia, India, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines and Rest of Asia-Pacific.